CAR T-Cell Immunotherapy Market Share, Size, Regional Outlook, Industry Analysis, Growth, Segmentation and Forecast To 2028

Report Summary

Eternity Insights has published a new study on Global CAR T-Cell Immunotherapy Market focusing on key segments as by Type (Monotherapy, Combination Therapy, Other), by Application (Hematologic Malignancies, Solid Malignancies, Other), and by region. This deep dive re-search report highlights the market and competitive intelligence across the key segments of the mar-ket. The report also considers the impact of COVID-19 on the global CAR T-Cell Immunotherapy Market.

The report considers 2018-2020 as historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the market drivers, challenges, and trends to accurately map the market scenario and competition. Moreover, key insights related to market having direct impact on the market will also be covered.

CAR T-Cell Immunotherapy Market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.

Global CAR T-Cell Immunotherapy Market Size, 2018-2028 (USD Million)

To learn more about this report

Request For Sample

Global CAR T-Cell Immunotherapy Market Segmentation:

CAR T-Cell Immunotherapy Market, By Type

• Monotherapy
• Combination Therapy
• Other

CAR T-Cell Immunotherapy Market, By Application

• Hematologic Malignancies
• Solid Malignancies
• Other

To learn more about this report

Request For Sample

Geographically, the market is categorized in to five regions as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America region dominates the global CAR T-Cell Immunotherapy market in terms of demand generation. The CAR T-Cell Immunotherapy market in Asia Pacific region is expected to grow at significantly high growth rate. The regional market is further sub-segmented and analyzed at granular level across key countries. The report will include market size and forecast for CAR T-Cell Immunotherapy market for below listed coun-tries across each region.

North America (U.S. and Canada), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, and Rest of Asia Pacific region); Latin America (Brazil, Mexico, and rest of the Latin America); Middle East and Africa (GCC, South Africa, and Rest of the Middle East and Africa).

Global CAR T-Cell Immunotherapy Market Taxonomy:

To learn more about this report

Request For Sample

Global CAR T-Cell Immunotherapy Market Competitive Landscape

The global CAR T-Cell Immunotherapy market analysis report covers detailed analysis of competitive scenario across globe. The report includes profiles of leading players covering below details

• Company Overview
• Financial Analysis
• Product Portfolio Analysis
• Strategic Overview
• SWOT Analysis

List of Companies Profiled in the report:

• AbbVie
• Celgene
• Kite Pharma
• Oxford BioMedica
• Novartis
• Gilead
• Pfizer
• Cellectis
• Bellicum
• Mustang Bio
• CARsgen Therapeutics
• Xyphos
• Minerva Biotechnologies
• Adaptimmune
• Ziopharm Oncology
• Aurora Biopharma
• Creative Biolabs
• Other Players of Specific Interest can be added based on requirement

Market Segmentation

Report Attributes	Details
The market size value in 2021	USD XX.XX Million
CAGR (2021 - 2028)	XX.XX %
The Revenue forecast in 2028	USD XX.XX Million
Base year for estimation	2021
Historical data	2018-2019
Forecast period	2022-2028
Quantitative units	Revenue in USD Million CAGR from 2021 to 2028
Report coverage	Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered	By Type Outlook, Application Outlook, Regional Outlook
By Type Outlook	Monotherapy, Combination Therapy, Other
By Application Outlook	Hematologic Malignancies, Solid Malignancies, Other
Regional scope	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country scope	U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey
Key companies profiled	AbbVie, Celgene, Kite Pharma, Oxford BioMedica, Novartis, Gilead, Pfizer, Cellectis, Bellicum, Mustang Bio, CARsgen Therapeutics, Xyphos, Minerva Biotechnologies, Adaptimmune, Ziopharm Oncology, Aurora Biopharma, Creative Biolabs
Customization Available	Yes, the report can be tailored to meet your specific requirements.

Key Benefits to the stake holders

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come

Table Of Contents

Table of Contents
CAR T-Cell Immunotherapy Market Report by Company, Regions, Types and Applications, Global Status and Forecast to 2025

1 Industry Overview of CAR T-Cell Immunotherapy

1.1 CAR T-Cell Immunotherapy Market Overview

1.1.1 CAR T-Cell Immunotherapy Product Scope

1.1.2 Market Status and Outlook

1.2 Global CAR T-Cell Immunotherapy Market Size and Analysis by Regions

1.2.1 North America

1.2.2 Europe

1.2.3 China

1.2.4 Rest of Asia Pacific

1.2.5 Central & South America

1.2.6 Middle East & Africa

1.3 CAR T-Cell Immunotherapy Market by Type

1.3.1 Monotherapy

1.3.2 Combination Therapy

1.4 CAR T-Cell Immunotherapy Market by End Users/Application

1.4.1 Hematologic Malignancies

1.4.2 Solid Malignancies

2 Global CAR T-Cell Immunotherapy Competition Analysis by Players

2.1 CAR T-Cell Immunotherapy Market Size (Value) by Players (2018 and 2019)

2.2 Competitive Status and Trend

2.2.1 Market Concentration Rate

2.2.2 Product/Service Differences

2.2.3 New Entrants

2.2.4 The Technology Trends in Future

3 Company (Top Players) Profiles

3.1 AbbVie

3.1.1 Company Profile

3.1.2 Main Business/Business Overview

3.1.3 Products, Services and Solutions

3.1.4 CAR T-Cell Immunotherapy Revenue (Value) (2014-2019)

3.1.5 Recent Developments

3.2 Celgene

3.2.1 Company Profile

3.2.2 Main Business/Business Overview

3.2.3 Products, Services and Solutions

3.2.4 CAR T-Cell Immunotherapy Revenue (Value) (2014-2019)

3.2.5 Recent Developments

3.3 Kite Pharma

3.3.1 Company Profile

3.3.2 Main Business/Business Overview

3.3.3 Products, Services and Solutions

3.3.4 CAR T-Cell Immunotherapy Revenue (Value) (2014-2019)

3.3.5 Recent Developments

3.4 Oxford BioMedica

3.4.1 Company Profile

3.4.2 Main Business/Business Overview

3.4.3 Products, Services and Solutions

3.4.4 CAR T-Cell Immunotherapy Revenue (Value) (2014-2019)

3.4.5 Recent Developments

3.5 Novartis

3.5.1 Company Profile

3.5.2 Main Business/Business Overview

3.5.3 Products, Services and Solutions

3.5.4 CAR T-Cell Immunotherapy Revenue (Value) (2014-2019)

3.5.5 Recent Developments

3.6 Gilead

3.6.1 Company Profile

3.6.2 Main Business/Business Overview

3.6.3 Products, Services and Solutions

3.6.4 CAR T-Cell Immunotherapy Revenue (Value) (2014-2019)

3.6.5 Recent Developments

3.7 Pfizer

3.7.1 Company Profile

3.7.2 Main Business/Business Overview

3.7.3 Products, Services and Solutions

3.7.4 CAR T-Cell Immunotherapy Revenue (Value) (2014-2019)

3.7.5 Recent Developments

3.8 Cellectis

3.8.1 Company Profile

3.8.2 Main Business/Business Overview

3.8.3 Products, Services and Solutions

3.8.4 CAR T-Cell Immunotherapy Revenue (Value) (2014-2019)

3.8.5 Recent Developments

3.9 Bellicum

3.9.1 Company Profile

3.9.2 Main Business/Business Overview

3.9.3 Products, Services and Solutions

3.9.4 CAR T-Cell Immunotherapy Revenue (Value) (2014-2019)

3.9.5 Recent Developments

3.10 Mustang Bio

3.10.1 Company Profile

3.10.2 Main Business/Business Overview

3.10.3 Products, Services and Solutions

3.10.4 CAR T-Cell Immunotherapy Revenue (Value) (2014-2019)

3.10.5 Recent Developments

3.11 CARsgen Therapeutics

3.12 Xyphos

3.13 Minerva Biotechnologies

3.14 Adaptimmune

3.15 Ziopharm Oncology

3.16 Aurora Biopharma

3.17 Creative Biolabs

4 Global CAR T-Cell Immunotherapy Market Size by Type and Application (2014-2019)

4.1 Global CAR T-Cell Immunotherapy Market Size by Type (2014-2019)

4.2 Global CAR T-Cell Immunotherapy Market Size by Application (2014-2019)

4.3 Potential Application of CAR T-Cell Immunotherapy in Future

4.4 Top Consumer/End Users of CAR T-Cell Immunotherapy

5 North America CAR T-Cell Immunotherapy Development Status and Outlook

5.1 North America CAR T-Cell Immunotherapy Market Size (2014-2019)

5.2 North America CAR T-Cell Immunotherapy Market Size and Market Share by Players (2018 and 2019)

6 Europe CAR T-Cell Immunotherapy Development Status and Outlook

6.1 Europe CAR T-Cell Immunotherapy Market Size (2014-2019)

6.2 Europe CAR T-Cell Immunotherapy Market Size and Market Share by Players (2018 and 2019)

7 China CAR T-Cell Immunotherapy Development Status and Outlook

7.1 China CAR T-Cell Immunotherapy Market Size (2014-2019)

7.2 China CAR T-Cell Immunotherapy Market Size and Market Share by Players (2018 and 2019)

8 Rest of Asia Pacific CAR T-Cell Immunotherapy Development Status and Outlook

8.1 Rest of Asia Pacific CAR T-Cell Immunotherapy Market Size (2014-2019)

8.2 Rest of Asia Pacific CAR T-Cell Immunotherapy Market Size and Market Share by Players (2018 and 2019)

9 Central & South America CAR T-Cell Immunotherapy Development Status and Outlook

9.1 Central & South America CAR T-Cell Immunotherapy Market Size (2014-2019)

9.2 Central & South America CAR T-Cell Immunotherapy Market Size and Market Share by Players (2018 and 2019)

10 Middle East & Africa CAR T-Cell Immunotherapy Development Status and Outlook

10.1 Middle East & Africa CAR T-Cell Immunotherapy Market Size (2014-2019)

10.2 Middle East & Africa CAR T-Cell Immunotherapy Market Size and Market Share by Players (2018 and 2019)

11 Market Forecast by Regions, Type and Application (2019-2025)

11.1 Global CAR T-Cell Immunotherapy Market Size (Value) by Regions (2019-2025)

11.1.1 North America CAR T-Cell Immunotherapy Revenue and Growth Rate (2019-2025)

11.1.2 Europe CAR T-Cell Immunotherapy Revenue and Growth Rate (2019-2025)

11.1.3 China CAR T-Cell Immunotherapy Revenue and Growth Rate (2019-2025)

11.1.4 Rest of Asia Pacific CAR T-Cell Immunotherapy Revenue and Growth Rate (2019-2025)

11.1.5 Central & South America CAR T-Cell Immunotherapy Revenue and Growth Rate (2019-2025)

11.1.6 Middle East & Africa CAR T-Cell Immunotherapy Revenue and Growth Rate (2019-2025)

11.2 Global CAR T-Cell Immunotherapy Market Size (Value) by Type (2019-2025)

11.3 Global CAR T-Cell Immunotherapy Market Size by Application (2019-2025)

12 CAR T-Cell Immunotherapy Market Dynamics

12.1 CAR T-Cell Immunotherapy Market Opportunities

12.2 CAR T-Cell Immunotherapy Challenge and Risk

12.2.1 Competition from Opponents

12.2.2 Downside Risks of Economy

12.3 CAR T-Cell Immunotherapy Market Constraints and Threat

12.3.1 Threat from Substitute

12.3.2 Government Policy

12.3.3 Technology Risks

12.4 CAR T-Cell Immunotherapy Market Driving Force

12.4.1 Growing Demand from Emerging Markets

12.4.2 Potential Application

13 Market Effect Factors Analysis

13.1 Technology Progress/Risk

13.1.1 Substitutes

13.1.2 Technology Progress in Related Industry

13.2 Consumer Needs Trend/Customer Preference

13.3 External Environmental Change

13.3.1 Economic Fluctuations

13.3.2 Other Risk Factors

14 Research Finding/Conclusion

15 Appendix

Methodology

Analyst Introduction

Data Source